The purpose of this trial is to evaluate the long-term (24 weeks) efficacy of prucalopride versus placebo in subjects aged 18 years and older with chronic constipation.
In this phase IV trial a total of 340 subjects (170 subjects per treatment group), with chronic constipation, are planned to be randomly assigned to double-blind treatment. The trial duration for a subject can be 26 to 28 weeks in total, including a 2- to 4-week run-in phase followed by a 24-week double-blind treatment phase. The patient will complete an e-diary. Adult subjects (≥18 to \<65 years of age) will take 2 mg prucalopride or matching placebo throughout the entire 24-week treatment period. Elderly subjects (≥65 years of age) will start at a dose of 1 mg prucalopride or matching placebo. In case of insufficient response the daily dose has to be increased to 2 mg (i.e. changed to 2 mg prucalopride or matching placebo).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
364
Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
Prucalopride 2 mg daily before breakfast 1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4
The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week Over the 24 Week Treatment Period
Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.
Time frame: Over 24 week treatment period
Percentage of Subjects With an Increase of ≥1 Spontaneous Complete Bowel Movement (SCBM) Per Week Up to 24 Weeks
Time frame: Over 24 week treatment period
Average Number of Spontaneous Complete Bowel Movements (SCBM) Per Week Up to 24 Weeks
Time frame: Over 24 week treatment period
Change From Baseline in Spontaneous Complete Bowel Movements Per Week at Up to 24 Weeks
Time frame: Baseline and Over 24 week treatment period
Percent of Subjects With an Average Weekly Frequency of at Least 3 SCBM by Week
Time frame: Over 24 week treatment period
Percent of Subjects With an Average Weekly Frequency of at Least 3 SCBM by 4-Week Treatment Period
Time frame: Over 24 week treatment period
Change From Baseline in Average Consistency Per SCBM at Up to 24 Weeks
Consistency measured using the 7-point Bristol scale where 1-2 indicate constipation (=hard/very hard), 3-4 are ideal stools (=normal), and 5-7 tending toward diarrhea.
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in Percent SCBM With a Consistency of Normal and Hard/Very Hard at Up to 24 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitaire Ziekenhuizen Leuven
Leuven, Flemish Brabant, Belgium
Cliniques Universitaires St. Luc
Brussels, Belgium
Huisartspraktijk Jaak Mortelmans
Ham, Belgium
Centre Hospitalier Universitaire Sart Tilman Liège
Liège, Belgium
Fakultní Thomayerova nemocnice s poliklinikou
Praha 4 - Krc, Prague, Czechia
Derma Plus s.r.o.
České Budějovice, Czechia
Oblastní nemocnice Kolín, a.s.
Kolín, Czechia
Diagnostika a Lécba Zažívacích Chorob, s.r.o.
Ostrava-Hrabuvka, Czechia
MONSE s.r.o
Prague, Czechia
Nemocnice Tábor, a.s.
Tábor, Czechia
...and 50 more locations
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in Straining Per SCBM at Up to 24 Weeks
Straining was evaluated on a 5-point scale (0=none, 1=mild, 2=moderate, 3=severe, or 4=very severe)
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in Percent SCBM With No Straining and Severe/Very Severe Straining at Up to 24 Weeks
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in Percent SBM With Sensation of Complete Evacuation at Up to 24 Weeks
Time frame: Baseline and Over 24 week treatment period
Time to First SCBM After Investigational Product Intake on Day 1 and Day 28
Time frame: Day 1 and 28
Change From Baseline in the Number of Bisacodyl Tablets Taken Per Week at Up to 24 Weeks
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in the Number of Days With Rescue Medication Taken Per Week at Up to 24 Weeks
Rescue medications include laxatives and enemas.
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in the Patient Assessment of Constipation - Symptom (PAC-SYM) Questionnaire Score at Up to the Final On Treatment Assessment Value
The PAC-SYM is a validated 12-item questionnaire for the evaluation of severity of symptoms of constipation in subjects with constipation. Items are rated on a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe. Total score ranges from 0 to 48. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-SYM total score was considered clinically meaningful.
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score at Up to the Final On Treatment Assessment Value
The PAC-QOL is a validated 28-item questionnaire for the evaluation of quality of life in subjects with constipation. Items are rated on a 5-point Likert scale: 0=not at all/none of the time, 1=a little bit/a little bit of the time, 2=moderately/some of the time, 3=quite a bit/most of the time, 4=extremely/all of the time. Total score ranges from 0-112. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-QOL total score was considered clinically meaningful.
Time frame: Baseline and Over 24 week treatment period
Change From Baseline in the Short Form-36 Health Survey (SF-36) Score at Up to the Final On Treatment Assessment Value
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.
Time frame: Baseline and Over 24 week treatment period